You are here

Online Treatment of Subretinal Neovascular Membranes from Laser Eye Injury

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-06-C-0397
Agency Tracking Number: A064-030-0270
Amount: $99,966.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: A06-T030
Solicitation Number: N/A
Solicitation Year: 2006
Award Year: 2006
Award Start Date (Proposal Award Date): 2006-09-01
Award End Date (Contract End Date): 2007-08-31
Small Business Information
20 New England Business Center
Andover, MA 01810
United States
DUNS: 073800062
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Daniel Hammer
 (978) 689-0003
Business Contact
 B. Green
Title: President of R&D Operations
Phone: (978) 689-0003
Research Institution
 Deeba Hussein
School of Medicine
Boston, MA 02215
United States

 (617) 638-8877
 Nonprofit College or University

Subretinal neovascular membranes (SRNM) are a deleterious complication of laser eye injury and retinal diseases such as age-related macular degeneration, choroiditis, and myopic retinopathy. The membranes are difficult to treat with conventional photocoagulation because they form near the fovea directly below sensitive photoreceptors. Photodynamic therapy is a promising treatment that acts by selective dye accumulation, activation by laser light, and disruption and clotting of the new leaky vessels. However, PDT surgery is currently not image-guided, nor does it proceed in an efficient or automated manner. This may contribute to the high rate of re-treatment. Physical Sciences Inc. and Boston University School of Medicine Department of Ophthalmology propose to develop an on-line, automated PDT treatment system. The system will be built around core technologies of scanning laser ophthalmoscopy and retinal tracking. The system will include fluorescein and ICG angiography as well as precise delivery of a PDT laser beam. Instrument components and software algorithms will be developed in Phase I and in Phase II the system will be built and tested in human subject trials on patients with SRNM. After the Phase II program, the system will be delivered to the U.S. Army Medical Research Detachment at Brooks City Base TX.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government